News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,450 Results
Type
Article (1139)
Company Profile (1)
Press Release (6310)
Multimedia
Podcasts (5)
Webinars (2)
Section
Business (2969)
Career Advice (41)
Deals (464)
Drug Development (1265)
Employer Resources (15)
FDA (216)
Job Trends (333)
News (4745)
Policy (387)
Tag
Academia (25)
Accelerated approval (2)
Adcomms (1)
Allergies (1)
Alliances (801)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (5)
Approvals (215)
Artificial intelligence (4)
Autoimmune disease (1)
Bankruptcy (6)
Best Places to Work (222)
BIOSECURE Act (2)
Biosimilars (2)
Cancer (31)
Cardiovascular disease (1)
Career advice (28)
Career pathing (2)
CAR-T (3)
Cell therapy (6)
Clinical research (1053)
Collaboration (19)
Compensation (1)
Complete response letters (1)
COVID-19 (55)
C-suite (12)
Data (24)
Depression (3)
Diabetes (2)
Diagnostics (29)
Diversity, equity & inclusion (6)
Drug discovery (6)
Drug pricing (2)
Duchenne muscular dystrophy (3)
Earnings (846)
Editorial (2)
Employer branding (4)
Employer resources (14)
Events (792)
Executive appointments (34)
FDA (228)
Friedreich's ataxia (1)
Funding (11)
Gene editing (1)
Generative AI (1)
Gene therapy (6)
GLP-1 (19)
Government (49)
Healthcare (175)
Huntington's disease (2)
Immunology and inflammation (6)
Infectious disease (56)
Inflammatory bowel disease (7)
Interviews (5)
IPO (198)
IRA (1)
Job creations (99)
Job search strategy (24)
Kidney cancer (1)
Labor market (3)
Layoffs (23)
Legal (99)
Lung cancer (1)
Lymphoma (5)
Management (2)
Manufacturing (1)
Medical device (15)
Medtech (15)
Mergers & acquisitions (269)
Metabolic disorders (2)
Neurodegenerative disease (3)
Neuropsychiatric disorders (3)
Neuroscience (27)
NextGen: Class of 2025 (80)
Non-profit (54)
Now hiring (23)
Obesity (1)
Opinion (12)
Pain (1)
Patents (1)
Peanut (1)
People (1175)
Pharmaceutical (2)
Phase I (290)
Phase II (385)
Phase III (517)
Pipeline (19)
Policy (6)
Postmarket research (55)
Preclinical (81)
Prostate cancer (2)
Radiopharmaceuticals (2)
Rare diseases (8)
Real estate (75)
Recruiting (5)
Regulatory (284)
Research institute (28)
Resumes & cover letters (5)
Schizophrenia (2)
Series A (3)
Series B (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (4)
Startups (91)
Tariffs (1)
The Weekly (5)
Vaccines (15)
Venture capitalists (2)
Weight loss (1)
Women's health (2)
Date
Today (4)
Last 7 days (8)
Last 30 days (23)
Last 365 days (435)
2025 (130)
2024 (489)
2023 (526)
2022 (767)
2021 (915)
2020 (867)
2019 (540)
2018 (416)
2017 (451)
2016 (375)
2015 (418)
2014 (247)
2013 (198)
2012 (226)
2011 (200)
2010 (163)
Location
Africa (15)
Alabama (2)
Asia (1219)
Australia (28)
California (75)
Canada (19)
China (10)
Colorado (2)
Connecticut (3)
Delaware (6)
Europe (1221)
Florida (6)
Georgia (1)
Illinois (21)
Indiana (1)
Japan (10)
Maryland (11)
Massachusetts (63)
Michigan (1)
Minnesota (2)
New Hampshire (2)
New Jersey (19)
New Mexico (1)
New York (5)
North Carolina (4)
Northern California (38)
Ohio (1)
Pennsylvania (6)
Rhode Island (1)
South America (15)
Southern California (22)
Tennessee (1)
Texas (3)
United States (230)
Washington State (6)
7,450 Results for "takeda".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in the past nine months.
February 25, 2025
·
2 min read
·
Tristan Manalac
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
Business
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.
January 30, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
May 5, 2025
·
3 min read
Press Releases
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
April 8, 2025
·
3 min read
Press Releases
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
April 30, 2025
·
1 min read
Drug Development
Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures
Takeda’s soticlestat, licensed from Ovid Therapeutics, did not significantly reduce seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome, respectively, according to two late-stage readouts on Monday.
June 17, 2024
·
2 min read
·
Tristan Manalac
Huntington’s disease
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration
Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave’s WVE-003 clinical-stage Huntington’s disease program—a potential $5 billion commercial opportunity, according to the biotech.
October 16, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
January 30, 2025
·
9 min read
Depression
Neurocrine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
January 28, 2025
·
2 min read
·
Tristan Manalac
1 of 745
Next
